Minerva Neurosciences (NASDAQ:NERV) Now Covered by StockNews.com

StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a report issued on Wednesday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $5.00 target price on shares of Minerva Neurosciences in a research report on Wednesday, February 26th.

Minerva Neurosciences Price Performance

NERV opened at $1.45 on Wednesday. The business’s 50-day moving average price is $1.61 and its two-hundred day moving average price is $1.94. Minerva Neurosciences has a 1 year low of $1.15 and a 1 year high of $3.69. The company has a market capitalization of $10.14 million, a price-to-earnings ratio of -3.30 and a beta of -0.50.

Minerva Neurosciences (NASDAQ:NERV) last released its quarterly earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.57. Sell-side analysts anticipate that Minerva Neurosciences will post -0.3 earnings per share for the current fiscal year.

Institutional Trading of Minerva Neurosciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. Apella Capital LLC acquired a new stake in shares of Minerva Neurosciences in the first quarter valued at about $35,000. Citadel Advisors LLC increased its position in shares of Minerva Neurosciences by 49.5% in the fourth quarter. Citadel Advisors LLC now owns 25,764 shares of the biopharmaceutical company’s stock valued at $57,000 after acquiring an additional 8,525 shares during the last quarter. Finally, Northern Trust Corp increased its position in shares of Minerva Neurosciences by 60.0% in the fourth quarter. Northern Trust Corp now owns 36,878 shares of the biopharmaceutical company’s stock valued at $82,000 after acquiring an additional 13,829 shares during the last quarter. Institutional investors and hedge funds own 34.56% of the company’s stock.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.